Pfizer Lyme Vaccine Achieves 70% Efficacy, Misses Trial Goal, Valneva Shares Plunge
Pfizer's experimental Lyme disease vaccine candidate showed over 70% efficacy in a phase 3 trial but missed its primary endpoint due to low infection rates, sending Valneva shares down 38% while Pfizer readies US and EU approval filings. Candidate LB6V may expand Pfizer's vaccine portfolio upon approval.
1. Trial Results Overview
The phase 3 trial tested LB6V in participants aged five years and above, demonstrating more than 70% efficacy in preventing Lyme disease but failing to meet its primary endpoint due to lower-than-projected infection rates during the study period.
2. Regulatory Plans
Pfizer plans to file for approval of LB6V in the United States and European Union, citing the strong efficacy signal despite the endpoint miss and emphasizing the urgent need for the first Lyme disease vaccine.
3. Market Impact
Valneva’s share price plunged 38% on the Paris exchange following the announcement of the endpoint miss, while Pfizer’s stock showed relative resilience as investors weigh the vaccine’s approval prospects and potential pipeline benefits.
4. Vaccine Candidate Details
LB6V targets the bacteria Borrelia burgdorferi by inducing specific antibodies, aiming to prevent the world's most common tick-borne illness which affects an estimated 14% of the global population and may increase with climate change.